A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma
Mutational Analysis and Serum Proteomic characterization of patient samples: prelude to the MMRC sponsored trial of the multi targeted kinase inhibitor PKC412
A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)
Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma
“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma
Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents
Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)
